Skip to main content
GCAN
OTC Life Sciences

New Controlling Shareholder Takes Over, Cancels $260K+ Debt, Appoints New CEO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.194
Mkt Cap
$183.365K
52W Low
$0.036
52W High
$3.6
52W Position info
439% above low
Off High info
95% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

GCAN has more than doubled off its 52-week low of $0.036 on light trading volume (0.1× avg).

Summary

A new controlling shareholder has taken over Greater Cannabis Company, acquiring 96.62% of voting power, canceling over $260,000 in debt, and appointing a new CEO and Chairman to lead a restructuring effort.


Key Events · Corporate Governance and Compliance · GCAN

  • Change of Control

    Trafalgar Asset Management, LLC acquired 100% of Series A and Series B Preferred Stock, gaining approximately 96.62% of the aggregate voting power of the company.

  • Significant Debt Cancellation

    The company's outstanding convertible promissory notes totaling over $260,000 (plus accrued interest) were compromised, settled, and extinguished, significantly improving the balance sheet.

  • New Leadership Appointed

    Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and a Director. Former CEO Aitan Zacharin resigned from all officer positions and will resign as a director.


Analysis · GCAN · Life Sciences

This filing marks a critical turning point for Greater Cannabis Company, which was previously facing severe financial distress and going concern doubts. The acquisition of 96.62% voting control by Trafalgar Asset Management, LLC, coupled with the cancellation of over $260,000 in convertible debt (an amount exceeding the company's market capitalization), significantly improves the company's balance sheet and addresses immediate liquidity concerns. The appointment of Porfirio Sanchez Talavera, who has a background in restructuring and special situations, as the new CEO and Chairman, signals a strategic effort to revitalize the company under new leadership. This comprehensive restructuring provides a lifeline and a new direction for the company.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GCAN was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $183.4K. The 52-week trading range was $0.04 to $3.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GCAN - Latest Insights

GCAN
Oct 14, 2026, 1:06 PM EDT
Filing Type: PRE 14C
Importance Score:
7
Price at Filing: $0.470
Real-time Price: $0.470 info
Change: $0 (0%) info
Market Cap: $467.358K info
GCAN
Oct 13, 2026, 6:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.470
Real-time Price: $0.470 info
Change: $0 (0%) info
Market Cap: $467.358K info
GCAN
Aug 14, 2026, 1:44 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2301
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info
GCAN
Jul 31, 2026, 2:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.220
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info
GCAN
Jul 06, 2026, 5:21 PM EDT
Filing Type: SC 14F1
Importance Score:
9
Price at Filing: $0.19405
Real-time Price: $0.470 info
Change: Reverse Stock Split info
Market Cap: $467.358K info